ArticleJACC. Case reports2025
Artificial Intelligence-Based Electrocardiographic Analysis Facilitated Diagnosis of Hypertrophic Cardiomyopathy With Successful Treatment Using Mavacamten.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serial AI-Enabled Electrocardiogram Trajectories During Heart Failure Treatment: A Proof-of-Concept Case Series.JACC. Case reports · 2026Article
- Interpreting Serial AI-ECG Changes During Heart Failure Therapy: From Disease Detection to Disease Tracking.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite a prevalence of 1 in 500, it is estimated that 85% patients with hypertrophic cardiomyopathy (HCM) may be underdiagnosed or misdiagnosed. There are emerging data on role of artificial intelligence enhanced 12-lead electrocardiogram (AI-ECG) in detection of HCM. CASE SUMMARY: In the current report, we describe the case of a 61-year-old man who was diagnosed with obstructive HCM using AI-ECG, performed as part of an executive physical with subsequent successful initiation and therapeutic response to mavacamten. DISCUSSION: An earlier and accurate diagnosis of HCM is a major unmet need and there are major efforts to enhance the ability a clinician to diagnose HCM as early as possible to be able to institute optimal therapies. TAKE-HOME MESSAGES: The case describes the use of AI-ECG to diagnose HCM appropriately in a 61-year-old symptomatic patient with no previous knowledge of the disease. Following an appropriate diagnosis of HCM, the patient was initiated on the novel cardiac myosin inhibitor mavacamten, with an excellent clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.